Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT327 combination therapy master protocol in first-line non-small cell lung cancer
2024-515764-31-00Phase 3Authorised
- Sponsor
- BioNTech SE
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-emergent adverse events, Dose interruption, reduction, and discontinuation due to adverse events and 3 more. Planned start Jun 2025; status: authorised.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515764-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515764-31-00.